An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Condition(s) studied

Investigational drug(s) / intervention(s)

Alectinib: Participants will receive alectinib in accordance with local clinical practice and local labeling.

Study summary

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

Eligibility

Primary outcome measure(s)

• Investigator-Confirmed Progression-Free Survival (PFS) According to the Local Standard of Care or per Response Evaluation in Solid Tumors (RECIST) - Cohort 1 — From the first administration of alectinib to the date of first documentation of disease progression, or death due to any cause, whichever occurs first (up to 4 years)
• Investigator-Confirmed PFS According to the Local Standard of Care or per RECIST - Cohort 2 — From the first administration of alectinib to the date of first documentation of disease progression, or death due to any cause, whichever occurs first (up to 2 years)
• Choice of the Next Line of Treatment (LoT) Post-Alectinib — Up to approximately 1 year
• Duration of Next LoT — Up to approximately 1 year
• Reasons for Discontinuation of Next LoT — Up to approximately 1 year

Trial sites (116)

+ 76 more sites — see the full list on the official registry below.

More Hoffmann-La Roche trials in China

Other trials for the same condition